company background image
APGE logo

Apogee Therapeutics NasdaqGM:APGE Stock Report

Last Price

US$47.32

Market Cap

US$2.7b

7D

-1.6%

1Y

52.3%

Updated

24 Dec, 2024

Data

Company Financials +

Apogee Therapeutics, Inc.

NasdaqGM:APGE Stock Report

Market Cap: US$2.7b

APGE Stock Overview

Through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. More details

APGE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Apogee Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Apogee Therapeutics
Historical stock prices
Current Share PriceUS$47.32
52 Week HighUS$72.29
52 Week LowUS$27.05
Beta0
1 Month Change8.88%
3 Month Change-18.00%
1 Year Change52.30%
3 Year Changen/a
5 Year Changen/a
Change since IPO122.89%

Recent News & Updates

We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate

Nov 14
We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis

Nov 10

Recent updates

We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate

Nov 14
We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate

Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis

Nov 10

We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate

Jun 20
We're Not Very Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn Rate

Apogee Therapeutics: Infrequent Dosing Advantage In Biotech Play

Jun 18

We're Interested To See How Apogee Therapeutics (NASDAQ:APGE) Uses Its Cash Hoard To Grow

Mar 05
We're Interested To See How Apogee Therapeutics (NASDAQ:APGE) Uses Its Cash Hoard To Grow

Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management

Mar 05

We're Not Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn

Nov 21
We're Not Worried About Apogee Therapeutics' (NASDAQ:APGE) Cash Burn

Shareholder Returns

APGEUS BiotechsUS Market
7D-1.6%-3.3%-0.4%
1Y52.3%-2.7%24.8%

Return vs Industry: APGE exceeded the US Biotechs industry which returned -1.9% over the past year.

Return vs Market: APGE exceeded the US Market which returned 23.9% over the past year.

Price Volatility

Is APGE's price volatile compared to industry and market?
APGE volatility
APGE Average Weekly Movement8.8%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: APGE has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: APGE's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
202291Michael Hendersonwww.apogeetherapeutics.com

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.

Apogee Therapeutics, Inc. Fundamentals Summary

How do Apogee Therapeutics's earnings and revenue compare to its market cap?
APGE fundamental statistics
Market capUS$2.69b
Earnings (TTM)-US$146.66m
Revenue (TTM)n/a

0.0x

P/S Ratio

-18.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
APGE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$146.66m
Earnings-US$146.66m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.58
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did APGE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 04:36
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Apogee Therapeutics, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charlie YangBofA Global Research
Julian HarrisonBTIG
Edward NashCanaccord Genuity